
Kluwer Patent Blog

Norway: Idenix v. Gilead, District Court of Oslo, 12-155575TVI-OTIR/01 and 13-170456TVI-OTIR/01, 21 March 2014

Lars Erik Steinkjer (Wikborg Rein) · Wednesday, July 8th, 2015

Both parties' patents in dispute relate to chemical compounds that are appropriate for use in pharmaceutical drugs, in particular for the treatment of flaviviridae infections such as hepatitis C virus infections. Ruling that Idenix' patent lacks a sufficiently clear description, and that Gilead's patent is novel and inventive, the Oslo District Court declared Idenix' patent invalid and handed down the judgment in favour of Gilead.

A [full summary](#) of this case has been published on [Kluwer IP Law](#).

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please [subscribe here](#).

Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how [Kluwer IP Law](#) can support you.


79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT
The Wolters Kluwer Future Ready Lawyer
Leading change



This entry was posted on Wednesday, July 8th, 2015 at 3:30 pm and is filed under [Case Law](#), [Chemical Engineering](#), [Norway](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.